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SUMMARY  
 
Title: Fungal Infections in the Intensive Care Unit 
Author: Dajana Džeko 
 
Background and Aims: Treating infections in patients at the intensive care unit is a 
complex matter which is nevertheless complicated by the critical state that the patients are 
usually in. The mortality rate due to fungal infections haven’t changed much in the last few 
years and so; dealing with fungal infections in the setting of critically ill patients can be 
challenging and there is an ongoing need for more research and for the development of 
new approaches. While previous discoveries of antifungal drugs were deemed successful 
in treatment, they created room for emergence of new fungal species and the widespread 
use of antibiotics and antifungal drugs has led to a growing resistance. Difficulties with 
early detection of fungal infections are currently still problematic while it has been shown to 
be crucial for the success of the treatment. With a shift in species and emerging 
resistance, while diagnostics and mortality rates aren’t getting much better; new 
approaches to fungal infections in the ICU (Intensive Care Unit) are being sought for.  
 
Methods: PubMed and Google Scholar were used to find relevant material. Search terms 
included but were not limited to: Invasive Candidiasis, ICU, treatment, Aspergillosis, risk 
factors etc. The primary criteria for study selection were evidence-based research and 
quality of design. 
 
Findings: Predictive rules to select high-risk patients who might benefit from prophylactic 
antifungal therapy have been found to be successful when used in combination with a 
clinical suspicion of fungal infection; but still need to be incorporated into clinical praxis. 
New diagnostic techniques (β-D-glucan, PCR) are under development and would lead to 
faster recognition of patients with fungal infections and hence faster administration of 
treatment; which has been shown to positively affect the survival rate. The recommended 
treatment has changed toward newer antifungal drugs but also depend on the age of the 
patient, immune status, localization of infection and isolated fungal species.  
 
Key words: Invasive fungal infection, Candidemia, Invasive aspergillosis, ICU. 
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SAŽETAK 
 
Naslov: Gljivične infekcije u jedinici intenzivnog liječenja 
Autor: Dajana Džeko 
 
Pozadina i ciljevi: Liječenje infekcija kod pacijenata u jedinici intenzivnog liječenja je 
složeno, a dodatno se komplicira životno ugrožavajućim stanjem u kojem su pacijenti. 
Stopa smrtnosti zbog gljivičnih infekcija nije se znatno promijenila u posljednjih nekoliko 
godina. Stoga u okruženju kritično bolesnih pacijenata bavljenje gljivičnim infekcijama još 
uvijek je izazovno i postoji potreba za daljnjim istraživanjem i razvojem novih pristupa. 
Prethodna otkrića antifungalnih lijekova su bila uspješna u liječenju, ali su stvorila prostor 
za pojavu novih gljivičnih vrsta, a široko korištenje antibiotika i antifungalnih lijekova dovelo 
je do sve veće rezistencije. Još uvijek postoje poteškoće u ranom otkrivanju gljivičnih 
infekcija iako znamo da je upravo to presudno za uspjeh liječenja. Uz današnju pojavu 
novih vrsta gljiva i porast rezistencije traže se novi pristupi dijagnostici i liječenju gljivičnim 
infekcijama u jedinici intenzivnog liječenja (JIL). 
 
Metode: PubMed i Google znalac upotrijebljeni su za pronalaženje relevantnog materijala. 
Izrazi za pretraživanje su uključivali, ali nisu bili ograničeni na: invazivnu kandidijazu, JIL, 
liječenje, aspergiloza, čimbenike rizika itd. Primarni kriteriji za odabir studija bili su 
istraživanja temeljena na dokazima i kvaliteta dizajna studija. 
 
Nalazi: Postoje pravila za odabir visokorizičnih bolesnika koji bi mogli imati koristi od 
profilaktičke antifungalne terapije i pokazala su se uspješnima kada se koriste u 
kombinaciji s kliničkom sumnjom na gljivičnu infekciju,  ali još uvijek treba koristiti dobru 
kliničku praksu. Nove dijagnostičke tehnike (β-D-glukan, PCR) su u razvoju i dovode do 
bržeg prepoznavanja bolesnika s gljivičnim infekcijama i time bržem početku liječenja; što 
se pokazalo da pozitivno utječe na stopu preživljavanja. Preporučeno liječenje se 
promijenilo prema novijim antifungalnim lijekovima, ali također ovisi o dobi pacijenta, 
imunosnom stanju, lokalizaciji infekcije i izoliranim vrstama gljiva. 
 
Ključne riječi: Invazivna gljivična infekcija, Kandidemija, Invazivna aspergiloza, JIL. 
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1. INTRODUCTION 
 
Fungal infections are a major burden of mortality and morbidity in the critical care setting 
and are one of the leading causes of nosocomial infections despite recognition of risk 
factors and improvement in infection prevention. As one of the leading causes of infections 
in the ICU (Intensive Care Unit), fungi cause opportunistic infections (infection develops 
when the hosts’ immune system is impaired) (8). There are many different fungal species 
that can be isolated in critically ill patients but the most common species are Candida, 
Aspergillus and Mucorales (1) where Candida is by far the most prominent cause of 
nosocomial fungal infections (8). Candida exists as part of the normal flora of the skin, the 
gastrointestinal and the genitourinary tract of healthy humans and colonizes the mucus 
membranes of 30-60% of humans (2, 9). Candidemia is the fourth most common cause of 
nosocomial bloodstream infections in the USA (3, 4) and the 6th-10th in Europe (2). Studies 
show that 80% of cases of severe invasive fungal infections are due to Candida spp and 0, 
3-19% are due to Aspergillus spp. Since the critically ill patients who are treated for 
invasive fungal infections are a very heterogeneous group in combination with the finding 
of Candida spp. being responsible for 17% of all infections in a worldwide ICU prevalence 
study; the approach to these infections is complex but of high importance. Selecting which 
patients would benefit the most from antifungal therapy, which drug to use, the right dose 
and duration of treatment is a challenge. Since the occurrence of infections is changing 
(species) and the emergence of resistance to antifungal agents (3, 9) it is of great 
importance to be cautious when treating these infections. The recognition of risk factors for 
fungal infections has been somewhat established, where multiple studies have agreed on 
which the major risk factors are. There have been several attempts of creating prediction 
rules using these risks, to single out the high-risk patients who would benefit the most from 
the treatment. The search for prediction rules is indeed valid, considering the fact that 10-
40% of cases of candidemia are associated with sepsis or septic shock (2). Other fungal 
species are far less common with unique risk factors and will be mentioned only briefly. 
 
Treating fungal infections, especially in patients in the ICU (Intensive Care Unit), is a 
delicate and important matter since the performance of different antifungal agents affects 
patients’ mortality. Studies have shown that episodes of invasive candidiasis occur 5-10 
times more often in the ICU compared to other wards and that two thirds of candidemia 
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occur in the ICU or on surgical wards (10). The mortality remains high (11) and there are 
still difficulties considering the diagnosis and treatment, while it has been established that 
early treatment increases survivability (5, 12). New insights into diagnostics and 
therapeutic strategies have changed the approach towards fungal infections. This paper is 
presenting the latest consensus, to this date, considering epidemiology, risk factors, 
diagnostics and treatment of fungal infections in the ICU. 
 
2. EPIDEMIOLOGY OF FUNGAL INFECTIONS IN THE ICU 
 
2.1 Candida Infections 
 
Candida spp. represent a great proportion of nosocomial fungal infections and is the 4th 
most common blood stream infection in USA (3, 4) while being the 6th-10th in population-
based European studies (2). The absolute majority of invasive fungal disease due to 
Candida species (over 90%) is due to the five most common pathogens C. albicans, C. 
tropicalis, C. glabrata, C. parapsilosis and C. krusei (7). A shift from albicans to non-
albicans species and to former non-pathogenic species has been observed. This might be 
explained with the fact that we can now detect new species in the laboratories and also 
due to an increase in the number of vulnerable people (1). Around 50% of the isolated 
species detected are C. albicans but the rate of identified nonalbican species are 
increasing (2, 4). Non-albican species that are becoming important pathogens are C. 
glabrata in northern Europe, Canada and the United States and C. parapsilosis in southern 
Europe, Asia and South America (3). The incidence is age-specific, with the maximal rates 
at the extremes of age (3). The incidence in reality might be higher than noted because of 
the low rate of positive blood cultures and the difficulty in making a diagnosis of 
candidiasis without candidemia (1). Candidiasis is the leading cause of fungal infections in 
the ICU (Intensive Care Unit), ranging from 1 to 10/1000 ICU admissions (2) and is an 
important cause of morbidity and mortality in ICU patients (1). The mortality rate differs 
significantly between patients. The mortality rate for a patient who has developed 
candidiasis or has multifocal colonization is 30-50% (4, 6) versus a patient without this 
diagnosis, 8-14%, or with unifocal colonization (13).  
 
Virulence and antibiotic susceptibility vary between different candida species and of note is 
that antifungal agents (especially azoles) have been associated with a consecutive 
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infection with C. glabrata and C. krusei (2, 3). C. parapsilosis and C. krusei are less 
virulent than C. albicans, C. tropicalis and C. glabrata. C. dubliniensis, C. lusitaniae, C. 
kefyr, C. guilliermondii are less frequent and are associated with specific hosts or with 
susceptibility patterns. C. dubliniensis is common in immunosuppressed individuals, 
especially in HIV-infected patients (3). A newly discovered, multidrug-resistant species is 
C. auris which causes invasive nosocomial infections (2). 
  
Invasive candidiasis can be divided into candidemia and deep-seated tissue candidiasis, 
where candidemia is more common. The deep-seated infection arises from direct 
inoculation to a sterile site, or due to earlier or unrecognized hematogenous dissemination. 
It can lead to secondary candidemia or stay localized (3). Other studies divide the Candida 
related diseases into three categories; candidemia with or without endophthalmitis, 
disseminated hematogenous infection with deep organ involvement and chronic 
disseminated candidiasis (1). 
 
2.2 Non-Candida Infections 
 
Aspergillus is a genus with ≥180 species but only a few cause infections in humans.  This 
group of fungi has a wide environmental distribution and can be found in soil, water, air, 
decomposing organic matter and ventilation systems. The species that are most clinically 
important are; A. fumigatus, A. flavus, A. niger, A. terreus, and A. nidulans (1, 8). 
Nesartorya udagawae has emerged with increasing clinical impact (1). The clinical 
characteristics of an infection (degree of infection, response to treatment and outcome) 
depend on the patient’s immune status. Aspergillus species can cause allergic 
hypersensitivity reactions (rhinitis, asthma, pneumonitis, ABPA (Allergic Broncho-
Pulmonary Aspergillosis)) or more serious invasive (pulmonary) disease. The 
manifestations of the invasive disease once again depend on the immune status of the 
host. In neutropenic patients it tends to lead to disseminated extrapulmonary disease 
through hematogenous or continuous spread, while it tends to lead to localized disease in 
non-neutropenic patients (8). The incidence in patients depends on the immune status and 
is in a decreasing manner; patients with hematopoietic stem cell transplantation, stem cell 
transplantation, solid organ transplantation, HIV and hematologic malignancy.  
 
When Aspergillus species have been isolated in a patient, it is difficult to discriminate 
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between colonization and infection (1)  but what is known is that it is a bad prognostic 
marker (8). Overall mortality ranges between 17-90 % depending on the type of infection 
and immune status of the patient, with the highest rate in patients who are liver transplant 
recipients (1, 8). 
 
Mucormycosis is a rare but serious infection with emerging importance and the most 
common genera are Rhizopus, Mucor and Rhizomucor (1). Other genera are Lichtheimia, 
Cunninghamella, Apophysomyces, Saksenae and other species. They cause an invasive 
fungal infection and are considered a fungal emergency.  Mortality depends on the 
underlying conditions and ranges from 19-35 % without any underlying condition and up to 
66 % for malignancy (1, 14, 15). The most common sites of infection are the sinuses, lung 
and the skin (in a decreasing order) but the central nervous system and gastrointestinal 
tract have also been described (15, 16). 
 
Infections with rare yeast species have been associated with specific conditions and exist 
as opportunists, causing invasive infections in selected patients. Cryptococcus, 
Histoplasmosis and Pneumocystis usually cause invasive disease in patients with severe 
T-lymphocyte dysfunction. Other fungal species that are even more rare but can be seen 
in the ICU (Intensive Care Unit) setting are; Fusarium, Scedosporium, Trichosporon, 
Hansenula, Rhodotorula and Malassezia (8, 17). According to the latest ESCMID 
guidelines (to date) one should keep in mind that almost all of these rare invasive fungal 
infections are considered intrinsically resistant to echinocandins when deciding for 
treatment in the ICU (17). 
 
3. RISK FACTORS FOR FUNGAL INFECTIONS IN THE 
ICU 
 
There is an overlap of the risk factors for different fungal species and with the 
characteristics of critically ill patients. Generally speaking, the risk increases when several 
areas of a host’s defense mechanisms are impaired (8). There are numerous known risk 
factors for invasive candidiasis in the ICU but the ones that have been supported most 
frequently by different studies are central venous catheter, recent surgery and broad-
spectrum antibiotics (3, 4), see table 1. Patients from the surgical ICU and especially 
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patients who underwent abdominal surgery, experienced anastomotic leakages and had 
more than one surgery are considered to be at a higher risk (3, 6). Regarding the 
increasing age of patients treated in the ICU and the growing number of comorbidities, 
more and more patients have several risk factors. These are therapy with 
immunosuppressive agents, neutropenia, TPN (Total Parenteral Nutrition), diabetes 
mellitus, pancreatitis, renal insufficiency, high disease severity score (APACHEII>20), 
major trauma, solid organ transplants and hematologic malignancy (1-3). Considering 
colonization with Candida spp., it can be considered an independent risk factor for 
development of invasive candidiasis (1, 3, 5) and more so if the colonization is multifocal 
(6) and is assessed using the colonization index (2). Studies have had differing 
conclusions though. Some studies have concluded that it is the disruption in the hosts’ 
defenses that creates the association with developing IC (Invasive Candidiasis) and not 
the degree of colonization (8). In a prospective multicenter study at surgical ICUs, the 
colonization of urinary tract/rectum and a higher APACHEII score wasn't found to increase 
the risk of developing invasive candidiasis, while receiving antifungal agents was found to 
decrease the risk. A retrospective study didn't find any significant association between 
receiving corticosteroids, immunosuppressive drugs, abdominal surgery and chronic 
hemodialysis and being at an increased risk of developing candidiasis. They suggest 
receiving broad spectrum antibiotics, diabetes mellitus and new onset hemodialysis to be 
significantly associated with the risk (13). Worth noting is that the sample was small and 
the circumstances described were rare events. Studies have shown that mortality might be 
independently affected by the severity of the disease while not being greatly affected by 
the chosen antifungal drug or presence of a CVC (Central Venous Catheter) (18). 
Receiving prophylactic treatment (fluconazole) has shown emergence of Candida krusei in 
bone marrow transplanted patients (4). 
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Table 1. Risk factors associated with Candida spp. infections in the ICU 
Use of broad spectrum antibiotics 
Presence of central venous catheter 
Use of immunosuppressive drugs, glucocorticoids, chemotherapy 
Major trauma 
Recent surgery (particularly abdominal surgery with anastomotic leakage & ≥1 surgery) 
Neutropenia  
Solid organ transplantation 
Hematologic malignant disease 
Hemodialysis 
Pancreatitis 
Total parenteral nutrition  
Diabetes mellitus 
Multifocal colonization (colonization index ≥0,4) 
Bold indicates major risk factors. For further information see references (1-6) 
 
CVCs (Central Venous Catheters) have been recognized as a major risk factor for 
candidemia due to the discovery that Candida species produce biofilms and adhere to 
catheters and the observation that the fungal infection may persist until removal of the 
catheters (3). Biofilms have been associated with creating a higher resistance to antifungal 
drugs and to the hosts’ immune response (9). The effect of removal of central venous 
catheters hasn’t yet to be agreed upon with studies showing different results; making it into 
a controversial debate (11). A cohort of 842 adults from two randomized clinical trials didn’t 
find any significant effect of early CVC removal. Early removal was defined at two points in 
time; within 24 hours or 48 hours after initiation of antifungal therapy. They concluded that 
APACHEII score (disease severity score), older age and neutropenia were the most 
beneficial variables and that CVC removal should be individualized (19, 20).  A patient-
level review of 1915 patients from seven trials concluded that the impact of CVC removal 
depended on the APACHEII score; with significant impact for the three lower quartiles but 
no association with improvement in the highest APACHEII quartile (score >24) (18). This 
would again point to an individualized approach towards CVC removal. Studies have also 
shown that removing catheters during candidemia or abscess drainage in invasive 
candidiasis is an independent factor of mortality reduction (2, 21). When interpreting the 
results of some studies that found that the removal of CVCs is associated with better 
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mortality it should be noted that there is a bias toward better outcome since a patient has 
to be alive to have the CVC removed (11, 18). In conclusion, it is recommended by the 
latest IDSA guidelines (2016) that the CVC should be removed as soon as possible in non-
neutropenic patients with IC (Invasive Candidiasis), if the CVC is considered to be the 
source of the infection (7).  
 
Since there are many different risk factors associated with the development of a fungal 
infection and taking all of these into account would include a great scope of patients, there 
have been attempts to develop systems for guiding the clinical doctors in identifying the 
patients at the highest risk of developing such an infection. This is important because of 
the development of resistance but also from a cost-efficient perspective. The Candida 
Colonization Index and the candida score are two examples of such attempts. Candida 
Colonization Index (CI) is the ratio of the culture positive sites over the total number of 
sites cultured for candida. Studies have concluded that a CI ≥ 0,4 could be used as the 
cutoff-value for introducing preemptive treatment (1, 3). Using a corrected Candida 
Colonization Index [(number of sites with heavy colonization/number of sites colonized) x 
colonization index] ≥0, 4 has had an efficiency of 100% of predicting IC (Invasive 
Candidiasis) (5). Candida Score (CS) is based on specified risk factors (surgery upon 
admission, TPN (Total Parenteral Nutrition), severe sepsis and multifocal colonization) and 
a value of CS > 2,5 puts the patient in the category of a high-risk patient, who might benefit 
from prophylactic treatment (1). A prospective cohort study compared the usage of CI, CS, 
β-D-glucan and anti-Candida antibodies for differentiating between colonized and infected 
non-neutropenic patients. CS was found to be better than CI considering both sensitivity, 
specificity and number of patients needed to be included to predict one infection (8,7 vs 
20,8 respectively). They suggest to use a cutoff-value for the CS >3, since the rate of 
patients having invasive candidiasis and a CS score <3 was 5 %. Considering the 
serological biomarkers, this study found that β-D-glucan had a sensitivity of 77,8 % and a 
specificity of 52,7 % while the anti-Candida antibodies wasn't found to be useful. (6).  
 
New studies have concluded that genetic variations, polymorphisms, might play a role in 
the susceptibility to candidemia. Studies have shown that the risk increases by 19 times in 
ICU (Intensive Care Unit) patients in the presence of newly discovered single-nucleotide 
polymorphisms. Disease progression has been associated with cytokine polymorphisms 
despite antifungal treatment. Polymorphism in the TLR/interferon pathway has also been 
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shown to increase the susceptibility in ICU patients vs. controls matched for underlying 
diseases (2, 3). These findings have opened up for further interest in genetic risk factors 
where one might speculate that the possibility of screening for specific polymorphisms 
could be a future method of selecting patients who would benefit from prophylactic 
antifungal therapy.  
 
Regarding Aspergillus spp., there are often multiple risk factors present in the patients who 
develop IA (invasive aspergillosis) at the ICU. The first risk factor to be recognized, since 
several decades ago, is neutropenia. Today it is believed that it's not only the number of 
neutrophils that matters, but also the overall neutrophil functional status. Very often 
though, compromised immune functional status and neutropenia coincide. The duration 
and degree of neutropenia plays an important role as well and this concerns recipients of 
solid organs, especially lung (1). The recognized risk factors for developing IA are 
immunocompromised status with hematologic malignancy, neutropenia, stem cell and solid 
organ transplant recipients (especially lung) and steroid treatment (1, 8). Corticosteroids 
have been recognized as a major risk factor (8) and a category of patients who have been 
noted to have an increasing incidence are patients with chronic obstructive pulmonary 
disease who are treated with corticosteroids (8). Other risk factors are prior antibiotic 
treatment, AIDS, H1N1 infection, chronic granulomatous disease, acute renal failure and 
receiving treatment with TNF-α inhibitors (1). 
  
The risk factors for mucormycosis in critical care setting are neutropenia, diabetes, 
hematopoietic stem cell transplantation and penetrating trauma (14) but also include 
malignancy, deferoxamine treatment and renal failure (1, 15). Iron overload may be a risk 
factor and so an adjunctive treatment for patients at risk might be to induce iron depletion 
through chelators and preferably the new agent deferasirox (1, 22). Infections of rare 
invasive fungal species have also been noted due to using contaminated medical devices 
such as tongue depressors and bandages (8, 23). 
  
Considering the importance of the immune system and host defenses that are involved in 
fungal infections, it has been stipulated that this knowledge might be used in future 
treatment options. Different parts of the immune defense (cells, cytokines) have been 
recognized to be of value in different phases of a fungal infection (24). Research on mice 
have shown that the IL-1R/TLR system plays a role in developing disease due to C. 
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albicans and A. fumigatus and is one of the strategies that might be developed for further 
targeting the development of invasive fungal infections in humans (8).  
 
4. DIAGNOSIS OF FUNGAL INFECTIONS 
 
4.1 Traditional Methods 
 
4.1.1 Candida Infections 
  
The diagnostic methods can be divided into direct and indirect methods (3). Direct 
methods are cultures of samples of blood or tissue from sites that are normally sterile. 
Cultures have a sensitivity ranging from 21-71%, have a long incubation time and are 
usually negative in deep-seated candidiasis (3). Cultures are also often negative when 
prophylaxis with fluconazole has been used (1) and they are not considered optimal for the 
diagnosis of candidemia or deep-seated candidiasis (2). After identifying Candida on blood 
cultures or with direct microscopy, the PNA-FISH method can be used to differentiate 
between different Candida species (8) or to identify the ones that are likely to be 
fluconazole-resistant  (16). 
  
Indirect diagnostic methods are for example biomarkers and PCR assays. The biomarker 
tests that have been shown the most interest are the ones detecting fungal cell wall 
components such as galactomannan antigens, antimannan antibodies and β-D-glucan. 
Biomarkers are specific but lack in sensitivity (1, 3). The negative predictive value in the β-
D-glucan is a major diagnostic benefit (3) and studies have shown that it could also be 
used to predict when to stop empirical treatment (2), but further investigation is always 
needed after obtaining a positive test result (16). A retrospective case-control study found 
that the best sensitivity/specificity ratio for testing β-D-glucan was 0, 65/0, 74 respectively 
and that the detection of mannan was more specific while lacking in sensitivity. Finding a 
high correlation between invasive candidiasis and these two tests being positive; they 
suggest that β-D-glucan testing could be used as a first-line screening and depending on 
the value of the result; mannan detection could be indicated in a second step. 
Furthermore, they suggest that patients receiving antifungals, with negative blood cultures, 
could be monitored for glucanaemia and mannanaemia as to predict relapses (25). The 
 
12 
sensitivity of biomarker tests has been shown to be higher for C. albicans than for other 
Candida species. It is also of importance, that it has been concluded that a negative serum 
β-D-glucan doesn’t rule out invasive fungal infection, as long as the clinical picture is 
suggestive of it (26). The performance of PCR assays has had different results in different 
studies. Studies have shown that PCR-tests have a sensitivity of 60% for detecting 
candidemia (1). The sensitivity for detecting deep-seated candidiasis with negative blood 
cultures has been concluded to range from invaluable to as high as 89% in different 
studies (1, 3) while some studies have shown that it has a higher sensitivity than β-D-
glucan in patients with IC or deep-seated candidiasis (2). It has been shown that PCR is 
positive at an earlier point versus using direct methods for detection (cultures). There 
needs to be a standardization of the PCR-tests (3) and it is to date not commercially 
available (2). According to the ESCMID guidelines the recommended test for invasive 
candidiasis is galactomannan antigen and antibody (3). In conclusion, there are many 
different tests for detecting candida infections but none is completely satisfactory or 
superior to the other methods, and so it would be necessary to perform several diagnostic 
tests, and preferably to combine them, for a greater accuracy. 
 
4.1.2 Non-Candida Infections 
 
Direct microscopy is very valuable because results are achieved fast but also because 
culture isn’t a good method for identifying some species (eg. Mucorales), certain species 
have a unique appearance (eg. capsule of Cryptococcus species) and direct visualization 
confirms that the organism is in the specimen and excludes contamination (16). 
  
The gold standard for diagnosing aspergillosis is to prove its presence histologically but 
this can be problematic to achieve in critically ill patients and so; combining clinical and 
radiological findings with microbiological evidence might be more appropriate (8, 16). 
Cultures of respiratory specimens have been shown to be useful only in high-risk patients. 
Galactomannan and β-D-glucan are both cell wall components and are found in body 
fluids and indicate a probability of infection. Galactomannan antigens in serum haven’t 
been proven useful in the ICU but measuring it in BAL fluid (Bronchoalveolar Lavage) has 
shown a sensitivity of 50-88 % and specificity of 87 % and the galactomannan index can 
be calculated based on the concentration found in the sample (1, 8, 16). If it is not 
appropriate to obtain BAL, three sputum samples can be sent for microscopy and culture 
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(16). PCR testing has a high specificity and sensitivity but can't be used to differentiate 
colonization from infection and is to this date not recommended to be used as a diagnostic 
technique by itself (1, 16). Combining galactomannan tests with PCR increases the 
sensitivity and has led to earlier recognition and administration of treatment but of note, 
these tests are affected by the use of prophylactic or empirical antifungal drugs (16). 
Depending on which Aspergillus species that is isolated, there is an increased risk (A. 
flavus) or decreased risk (A. niger) of IA (invasive aspergillosis) (16). According to the 
EORTC/MSG consensus group, the diagnosis of aspergillosis can be based on three 
criteria; 1) risk and host factors, 2) clinical and radiological signs and symptoms, and 3) 
laboratory testing that indirectly or directly proves the existence of Aspergillus. Using these 
criteria, the diagnosis can then be divided into proven, probable and possible infection (27, 
28). A proven infection is a positive culture of a sterile site or a positive histopathological or 
cytopathologic examination. For a probable infection, all the three criteria mentioned need 
to be positive but the sites used for laboratory testing need not be otherwise sterile. 
Sputum, bronchoalveolar lavage etc. may be used. For a possible infection, the first and 
the second criteria need to be present but the evidence of Aspergillus on laboratory testing 
isn't necessary (1). The radiological tests that may be used are chest x-rays and CT scans, 
where the presence of the “halo sign” on the latter would be pathognomonic for the 
disease. The “halo sign” is a nodule with a dense center, surrounded by ground glass 
opacity (1). It is usually absent in patients at the ICU though (8) and the radiological 
findings might seem normal or non-specific in neutropenic patients with IA (pulmonary) 
who would more commonly have signs such as infiltrates, consolidations and nodules (16). 
 
There are different conclusions about the diagnostic methods to be used when suspecting 
mucormycosis. Diagnostic methods are overall deemed limited and histopathology is 
considered the only method that can confirm the presence of Mucorales, while PCR isn't 
routinely used but has been described and on radiological testing there are usually no 
specific findings (1). If an invasive fungal infection is suspected in a patient with suggestive 
lesions on a CT-scan together with a negative Aspergillus galactomannan serum test and 
negative BAL; an invasive mucormycosis infection should be suspected. In selected 
patients (hematologic malignancy, recipients of stem cell transplants) imaging with CT can 
show the “reverse halo sign” which can help differentiate mucormycosis from aspergilloma. 
The “reverse halo sign” is a ring of consolidation with a center of ground glass opacity, but 
the diagnostic value depends on the pre-test probability (14). 
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The latest ESCMID guidelines, to date, conclude that the three methods that are strongly 
recommended for diagnosis are direct microscopy, histopathology and culture and that 
histopathology may help differentiate Mucorales spp. from Aspergillus spp. Identifying the 
species and testing susceptibility is also strongly recommended for gaining 
epidemiological knowledge but not so much for guiding treatment since a significant 
association between minimal fungicidal concentration and clinical outcome hasn't been 
found. (14) 
 
Considering the Cryptococcus spp, the capsule antigen of C. neoformans and C. gattii can 
be tested for in serum and CSF. Testing for β-D-glucan is not appropriate for the 
Cryptococcus and Mucorales spp. since they don’t produce it (16, 17). It is also important 
to mention that when one is evaluating possible invasive fungal sinusitis (which could lead 
to serious complications such as spread to the CNS due to hematogenous or direct sinus 
extension) it is crucial to perform a cross-sectional CT or MRI imaging (16).  
 
4.2 New Methods 
 
Since Candida species are becoming increasingly resistant to antifungal drugs, it is 
becoming important to rapidly identify species, so that effective treatment can be started 
early. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF) is currently a promising method for rapid identification of bacterial and fungal 
organism once they have been isolated (1) and works by automatically analyzing the mass 
distribution of proteins (29). Turnaround time is 10-15 minutes and the diagnostic accuracy 
is at least 95 % (2) and 84-99 % when compared to conventional methods (30). MALDI-
TOF is gaining popularity as an accurate, fast and cost-effective new method of diagnosing 
infectious diseases (29). It is also considered to possibly become a future diagnostic tool 
for rare invasive fungal infections (17) (30). 
 
Peptide nucleic acid-fluorescence in situ hybridization (PNA-FISH) is a method that uses 
artificial PNA polymers. PNA is different from DNA or RNA with the phosphate ribose ring 
being replaced by a polyamide, making the backbone of PNA acyclic and neutral. This 
method uses hybridization of PNA probes to species specific regions of ribosomal RNA 
and has a high sensitivity and specificity. It has been shown to be able to differentiate 
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between Candida species after identified growth in blood cultures and does so within 
hours (1, 2, 8) and can be used with direct microscopy to identify Candida species that 
might be fluconazole-resistant (16). This could be of use when selecting antifungal agents. 
Studies concerning these new interesting technologies have been promising but they still 
need to be established into the diagnostic work-up and further studies need to be 
performed to evaluate the clinical benefits.  
 
5. PROPHYLACTIC, PREEMPTIVE AND EMPIRIC 
STRATEGIES 
 
5.1 Prophylactic Strategies 
 
Clinical studies have given little support for prophylactic treatment, unless for specific high-
risk groups (incidence of at least 10%) (12). Prophylaxis with fluconazole have been 
effective for patients who recently underwent abdominal surgery, have recurrent 
gastrointestinal perforations, anastomotic leakage (1, 3) or are recipients of bone marrow 
transplants (13). A study which compared prophylactic fluconazole with placebo in ICU 
patients didn’t find any significant difference in the incidence of candida infections, 
mortality or length of stay (10). Antifungal prophylaxis have been shown to reduce the 
incidence of candidemia by 50%, but there is to this date no evidence that has shown that 
the survival is increased (3) outside the group of bone marrow transplanted patients (13). It 
has been shown though, that survivability increases if preventative antifungal agents are 
administered early (5) and more specifically within 24-48 hours of the first positive blood 
culture; which is problematic since the culturing methods that are used to this date require 
48-72 hours to be able to test positive for yeast (12).  
 
A recent multicenter, randomized, placebo-controlled study used the echinocandin 
caspofungin as antifungal prophylaxis in ICU patients who were found to be at high risk of 
developing IC (Invasive Candidiasis). A clinical prediction rule was used to select patients. 
The study didn’t find any benefit in the high-risk ICU patients who were treated 
prophylactically with caspofungin. Of note is that the patients undergoing abdominal 
surgery were put in the same group as patients undergoing other types of surgeries. Since 
different types of surgeries carry different rates of risk of fungal infection, this could’ve 
 
16 
affected the outcome of the study (31).  
 
It is suggested that one should be careful with prophylactic recommendations because of 
the rising incidence of resistant Candida spp. and also due to the cost of the drugs. Hence, 
prophylaxis is considered useful only for the groups of patients that it has been shown to 
be effective for: patients with gastrointestinal anastomotic leakage, patients that had 
pancreatic or small bowel transplants, specific patients undergoing liver transplants and 
extremely low-birth-weight neonates in specific settings (3, 32). In a prospective study 
evaluating this concept, studying high risk surgical patients (recurrent gastrointestinal 
perforations/anastomotic leakage or acute necrotizing pancreatitis) patients were treated 
prophylactically with caspofungin and the study concluded that intra-abdominal IC 
(Invasive Candidiasis) was prevented in 95% of the patients. They administered a loading 
dose of 70 mg, followed by 50mg/day until the patient’s surgical condition was resolved 
(median duration of treatment was 16 days) (5). 
 
Administering echinocandins to prevent IC in patients at the ICU (Intensive Care Unit) is 
still being debated [reviewed in (33)]. Based on moderate quality evidence, the latest IDSA 
guidelines (2016), recommend administering fluconazole with a loading dose of 800mg 
and then 400 mg/day in high-risk patients at the ICU. With low quality evidence, they 
recommend echinocandins as an alternative. Caspofungin (70mg loading dose, then 50mg 
daily), anidulafungin (200mg loading dose, then 100mg daily) or micafungin (100mg daily) 
(7). 
 
Developing prediction rules for patients at high risk of developing IC and using these as 
guidance for prophylactic, preemptive and empirical therapy is complex and the results 
have been controversial. Most often, these studies have been retrospective and 
prospective studies are needed to validate the prediction rules before they can be used in 
clinical practice.  
 
A retrospective study aiming to find predictive rules for identifying patients at the surgical 
ICU who are at increased risk of developing candidiasis, found a set of criteria that 
identified 78% of the patients who would develop candidiasis. By using their rules, the 
patients needed to treat before preventing one case of candidiasis ranged from six to 19 
and the estimated cost was found to be lower than the estimated cost of treating a case of 
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candidiasis (5). Even though the sample was small and there needs to be prospective 
validation of using the suggested rule, it shows that antifungal prophylaxis in the ICU 
based on risk evaluation might be possible. 
 
Another retrospective multicenter study aimed to develop and evaluate clinical prediction 
rules in the ICU setting. They concluded that the best performing rule was any systemic 
antibiotic or central venous catheter with at least two of the following; TPN (Total 
Parenteral Nutrition), dialysis, major surgery, pancreatitis, steroid treatment or 
immunosuppression. They also specified on which number of days, since ICU admission, 
that these criteria should’ve been fulfilled to be marked as a factor in the prediction rules. 
In this study, by using these rules one might have been able to predict 34% out of all the 
cases of patients that developed IC (Invasive Candidiasis) (34).  
 
Three published clinical risk predictive models for invasive candidiasis were evaluated in a 
prospective multicenter study. These models took into account clinical risk factors only or 
they also incorporated Candida colonization parameters. The predictive models were 
applied prospectively on ICU patients who were admitted for at least 72 hours, to see if 
these models could be included in management algorithms. Cases were found by 
evaluating for EORTC-MSG criteria. 15 out of 615 patients developed invasive candidiasis 
and there were 11 infections due to C. albicans. When comparing the performance of the 
models that only used clinical risk factors, the results were different than in the previously 
published studies with better sensitivity but worse specificity and positive predictive value. 
When adding the candida colonization parameters post-hoc, the results improved, except 
for the sensitivity which decreased. The results of the performance of the colonization 
index were similar to the models that used clinical risk factors. It was concluded that risk 
predictive models should include both clinical risk factors and colonization parameters to 
achieve a higher performance (12).  
 
The presence of Aspergillus species in an immunosuppressed patient, whether it is 
colonization or infection, is a poor prognostic marker (1). Prophylactic treatment of 
aspergillosis has not been validated for use in the ICU, but has been administered in 
neutropenic patients (1).  
 
Considering prophylactic treatment of Mucorales spp. it is recommended to be provided to 
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immunosuppressed individuals with a previous diagnosis of mucormycosis, to prevent 
recurrence. The choice of drug should be the antifungal agent that was effective last time 
in combination with surgical resection. Neutropenic patients or individuals with a graft-
versus-host-disease outbreak should also be given prophylaxis with posaconazole (14). In 
complex situations such as preventing relapse in patients who were successfully treated 
for mucormycosis but need further immunosuppressive treatment for their underlying 
conditions, there are no clear guidelines and sufficient evidence based data is lacking. It is 
important to educate patients about the signs of relapse of a Mucorales spp. infection 
(such as facial swelling and black nasal discharge) and encourage them to seek medical 
attention if these signs appear. 
 
5.2 Preemptive Strategies 
 
It is of great importance that early presumptive treatment lowers mortality and increases 
survival of patients with invasive candidiasis. Retrospective observational studies have 
shown that early presumptive treatment lowers the mortality in patients with invasive 
candidiasis but this still has to be validated by prospective studies (3). When deciding 
which patients are best suitable for pre-emptive treatment, clinical prediction rules such as 
CS (Candida Score) can be used to select patients at high-risk of developing invasive 
candidiasis and these individuals’ serum biomarkers (β-D-glucan or PCR) would then be 
followed. Administering pre-emptive treatment based on elevated serum β-D-glucan has 
been shown to reduce the incidence of proven invasive candidiasis (2). 
 
A retrospective case-control study suggesting that β-D-glucan testing can be used as 
screening, with mannan test as a second step if indicated, propose an algorithm for 
preemptive treatment of patients at the ICU (Intensive Care Unit). They consider this being 
a very useful approach since the excess use of antifungal agents is expensive (25). The 
test that was used for detecting mannan epitopes poorly detects the mannan epitopes on 
C. parapsilosis, which is a species that was present frequently in the sample groups in this 
study. This could have affected the conclusions that were drawn from the study and might 
be considered significant since C. parapsilosis is currently becoming more common in 
southern Europe, Asia and South America (3). The CI (Candida Colonization Index) was 
suggested to be used only as a last step. Other studies have concluded though, that a CI 
> 0, 4 is the cutoff-value for preemptive treatment (1, 3). Preemptive treatment is not 
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indicated for patients with multifocal colonization of candida and risk factors for infection 
but without an established infection (1). It is instead suggested in patients with risk factors 
and positive serology (1). There is a need for more studies to establish which patients are 
suitable for pre-emptive therapy and since pre-emptive treatment would lead to more 
broad use of antifungal agents, there needs to be an evaluation of how this affects the 
epidemiology of fungal species (2). 
 
Preemptive treatment of aspergillosis is usually defined as the one administered when 
there's mycological evidence but no developed infection. The benefit with this, versus 
empirical therapy, is controversial (1). 
 
5.3 Empiric Strategies  
 
A majority of the patients (two thirds) at the ICU receive empirical antifungal treatment 
while it is still a controversial approach without completely conclusive results (35). Early 
empirical treatment has been recommended in selected patients (those with risk factors for 
IC (Invasive Candidiasis), sepsis of unknown cause and positive serum biomarkers) but its 
effect on outcome needs to be further investigated (2). Empirical therapy may also be 
administered to patients with refractory fever being treated with broad-spectrum antibiotics 
(1). Combining the CS (Candida Score) and serum β-D-glucan test results has been 
suggested to be used to guide empiric antifungal treatment (6). 
  
In studies that were powered for noninferiority, it has been shown that fluconazole, 
voriconazole and caspofungin are as effective as amphotericin B deoxycholate with less 
toxic effects and lower rates of discontinuation of treatment (3). As a result of studies like 
these, amphotericin B deoxycholate isn’t today the preferred first option for treatment of 
invasive candidiasis (2). Noninferiority studies have also shown that anidulafungin should 
be preferred over fluconazole, especially in treatment of C. albicans, despite the severity of 
the disease (3). Echinocandins have been shown to be a better choice over azoles and 
amphotericin B when considering survival rates and clinical outcome, especially 
considering infections with C. albicans and C. glabrata. (3)  
 
Concerning the removal of intravascular catheters in patients with candidemia and the 
resulting effect on survival and outcome, studies have had somewhat different 
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conclusions. There is a need for randomized, blinded studies of the effect that catheter 
removal might have on mortality and outcome and many retrospective studies that have 
been done to date have shown different outcomes (3). In a pooled patient-level analysis of 
seven randomized treatment trials, where the patients were treated with an echinocandin 
in combination with catheter removal, the conclusion was that two factors were concluded 
to be associated with improved survival (18).  
 
Studies have shown that, regardless of the type of invasive candidiasis and APACHE II 
score (disease severity score), an echinocandin should be considered the drug of choice. 
The latest ESCMID and IDSA guidelines state that documented invasive candidiasis 
(positive blood culture)  should be treated with echinocandins as a first line antifungal drug 
and in cases of unstable patients or patients with recent use of fluconazole (1). There are 
exceptions in some specific circumstances, where treatment with triazoles would be 
preferred. These scenarios are; treating for C. parapsilosis infection (since the minimal 
inhibitory concentration for echinocandins is high (18)), if the patient used echinocandins 
previously for a prolonged period or if the patient has meningitis, endophthalmitis or a 
urinary tract infection (11). Echinocandins is not suitable for urinary tract infections 
because of their pharmacokinetics; the active drug isn't excreted in urine (1). Exposure to 
echinocandins have been shown to induce resistance to the drug but also multidrug 
resistance (36) and the choice of drug would hence be a triazole (fluconazole), because 
empirical studies have shown that the patient in this case, after using an echinocandin, 
would most likely have developed a C. parapsilosis infection (3). Studies have also shown 
that in a specific subgroup of patients (stable, low-risk, likely to be fluconazole susceptible) 
(11) the drug of choice should be fluconazole instead of an echinocandin. The first line 
treatment in these patients should be a loading dose of 500 mg fluconazole and then 400 
mg (1, 3, 7). 
 
It has been suggested that clinical prediction rules might be used for starting empirical 
treatment and that the negative predictive value of β-D-glucan could be used to guide the 
discontinuation of the treatment (2). Echinocandins should be used until the patient 
reaches clinical stabilization, no matter the species of Candida that is in question (except 
C. parapsilosis) , since they have been proven to increase survival (3). Limiting the 
duration of treatment to a specific number of days has been debated and is highly 
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controversial. Some studies have concluded that, if the conditions are right, the treatment 
with intravenous echinocandins can be switched to oral azoles after five days (3). Other 
studies have concluded that there's a need of consecutive blood cultures and treatment for 
14 days after the last positive blood culture, with fundoscopy examination (to exclude 
endocular infection) and removal of central venous catheters and implanted devices (1). 
 
Based on moderate quality evidence, the latest IDSA guidelines (2016) recommend 
empirical treatment of non-neutropenic critically ill patients with risk factors for IC (Invasive 
Candidiasis) and no other known cause of fever, with an echinocandin. Administering 
caspofungin (70mg loading dose, then 50mg daily), anidulafungin (200mg loading dose, 
then 100mg daily) or micafungin (100mg daily) is recommended. Also with moderate 
quality evidence, fluconazole is recommended as an alternative treatment (800mg loading 
dose, then 400mg) if the patient hasn’t recently been exposed to azoles and the identified 
Candida species aren’t azole-resistant (7). 
 
Empirical treatment of aspergillosis is suggested to be administered to neutropenic 
patients at risk, with a prolonged febrile period, while having already received broad 
spectrum antibiotics (1). An echinocandin in combination with amphotericin B may be used 
(8). 
 
6. TREATMENT 
 
6.1 Candida Infections 
 
When managing Candida infections the treatment varies considerably and depends on 
many aspects; the specific Candida species responsible for the infection, the susceptibility 
to antifungal drugs, the anatomical location of the infection, the underlying immune status  
and comorbidities of the patient and the patients’  risk factors for infection.  
 
A randomized multicenter study compared voriconazole treatment with amphotericin B 
followed by fluconazole for invasive candidiasis in non-neutropenic patients. The median 
duration of treatment was 15 days and the intravenous catheters were removed in the vast 
majority of patients in both groups. Voriconazole was given intravenously 6mg/kg twice in 
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the first 24 hours, then 3mg/kg twice daily for three days, then 200mg orally twice daily. 
The conclusion was that it is as effective but with fewer toxic side effects compared to the 
regimen with amphotericin B/fluconazole (37). 
 
Treating invasive candidiasis with intravenous anidulafungin (200 mg loading dose, then 
100 mg/day) was compared to intravenous fluconazole (800 mg loading dose, then 400 
mg/day) in a randomized, double-blind, non-inferiority study. The majority of patients (97%) 
were non-neutropenic. The treatment lasted for ≥14 days after the last negative blood 
culture with improvement in symptoms and signs. Oral fluconazole (400mg daily) could 
also be administered to patients in both groups after ≥10 days of intravenous therapy. The 
results were successful in 75, 6% of patients treated with anidulafungin versus 60, 2% of 
the patients receiving fluconazole. The adverse effects were similar in both groups. While 
finding that anidulafungin was more effective than fluconazole in some circumstances (at 
the end of the therapy and at 2-week follow-up) but had a lower rate of success for 
infections with C. parapsilosis (echinocandins have a lower efficacy against this agent in 
general); it was concluded that overall, anidulafungin is non-inferior to fluconazole. Of 
note, patients with proven infection of C. krusei were excluded from the study (38). There 
are clinical scenarios though, when azoles may be more appropriate than echinocandins 
such as in patients with meningitis, endophthalmitis and candiduria (39). The emergence 
of resistance to echinocandins in C. glabrata and C. krusei has also been noted to be a 
clinically relevant problem and in these situations one might use a higher dose of 
fluconazole (800 mg/day) (8). 
 
Table 2. Recommended treatment for candidemia in non-neutropenic patients  
1st line Alternative regimen 
Caspofungin  
(70 mg loading dose, then 50 mg daily) 
Fluconazole 
(800 mg loading, then 400 mg daily) 
Micafungin  
(100 mg daily) 
Lipid-formulation Amphotericin B 
(3-5 mg/kg/day) 
Anidulafungin  
(200 mg loading, then 100 mg daily) 
 
Adopted from IDSA (infectious disease society of America) guidelines 2016 (7)  
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According to the new clinical guidelines from IDSA (see table 2) the recommended initial 
treatment for candidemia in non-neutropenic patients is an echinocandin. Caspofungin 
(70mg loading, then 50mg daily), micafungin (100mg daily) or anidulafungin (200 mg 
loading, then 100mg daily). Recommended alternative choices are fluconazole (800mg 
loading, then 400mg daily) in selected patients, unlikely to have fluconazole-resistant 
Candida species, and lipid formulation amphotericin B (3-5mg/kg daily) in case of 
intolerance, limited availability or resistance to other antifungal drugs. Transition from an 
echinocandin to fluconazole within 5-7 days is recommended for clinically stable patients, 
in the case of Candida species that are susceptible to the drug, and in whom repeat 
cultures on antifungal therapy are negative. For infections due to C. glabrata the transition 
to fluconazole or voriconazole is recommended in susceptible species. For infections due 
to C. krusei, voriconazole is recommended as a step-down therapy. For all cases of blood-
stream Candida infections; susceptibility of azole should be tested, a dilated 
ophthalmology exam performed within the first week of diagnosis and follow-up cultures at 
least every other day. Recommended duration of therapy is 2 weeks following negative 
blood culture results and resolution of candidemia related symptoms (7). 
 
Considering the echinocandin group of antifungal drugs, there are a few limitations that 
have inspired further research. Among these are the need for daily intravenous dosing, 
high cost, limited spectrum, emerging resistance and liver and cardiac toxicity. The 
continuous interest in this group of drugs has led to an exciting new discovery; their ability 
to prevent and treat Candida biofilm formation, and studies on caspofungin-coated medical 
devices is ongoing. Since Candida infections of medical devices are costly, this could be a 
first step towards a great discovery [reviewed in (33)]. 
 
6.2 Invasive Mold Infections 
 
Definitive treatment of aspergillosis is defined as treatment given to a patient with a proven 
infection. The drug of choice in IA (Invasive Aspergillosis) is voriconazole (1, 8) (6 mg/kg 
i.v. twice daily loading dose, then 4 mg/kg twice daily). Itraconazole and posaconazole are 
considered second line treatment options. When a single agent isn't successful, 
combination therapy may be used. Caspofungin together with amphotericin B can be used 
when treatment with other agents isn't successful or isn't appropriate because of adverse 
events. Amphotericin B has mostly lost its predominance because of its adverse effects, 
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where nephrotoxicity is one of the most common adverse effects. It has been noted that it 
is paradoxically less toxic at higher doses, though there are no differences in the outcome. 
Adjunctive treatment may be used, including Granulocyte-Colony Stimulating Factor and 
Interferon-Gamma and resection of the lesions might be needed in some cases (1). 
Duration of the treatment depends on the immune status of the patient. For a non-
immunosuppressed patient 6-12 weeks are suggested while an immunosuppressed 
patient is suggested to be treated until the immune status changes and the clinical and 
radiological signs and symptoms resolve. There is no need to achieve a negative 
laboratory test to certify the eradication of the fungus. Relapses may occur due to 
incomplete eradication or lack of sterilization of foci (1). 
 
The treatment options for mucormycosis are limited and the degree of difficulty to treat 
infections with this organism is higher than for other invasive fungal infections (40). The 
general consensus is that immediate treatment increases survival and a combination of 
pharmacological treatment with surgical debridement whenever possible and correction of 
the underlying risk factors is suggested (1, 16). Reversal of the predisposing risk factors 
has been concluded as an important step in the treatment of mucormycosis and examples 
are administering Granulocyte-Colony Stimulating Factor, preventing hyperglycemia, 
ketoacidosis and limiting to a minimal dose/ceasing treatment with glucocorticosteroids 
(14, 40). In the ESCMID guidelines, the drug of choice is amphotericin B in the liposomal 
or lipid-complex form (at least 5 mg/kg/day) and the use of amphotericin B deoxycholate is 
discouraged because of its severe adverse effects (14). Other studies conclude that 
amphotericin B in deoxycholate, lipid complex or liposomal form may be used in the doses 
1-1, 5 mg/kg/day, 5-7, 5 mg/kg/day and 5-10 mg/kg/day respectively (1).  
 
Combination therapy with amphotericin B and an echinocandin or deferasirox (an iron 
chelator) has also been suggested for mucormycosis but is controversial (16). A phase II 
trial showed that patients with mucormycosis had a higher mortality at 90 days if treated 
with deferasirox and was therefore not supportive of it as adjunctive therapy, while other 
studies claim that it reduces the risk of mucormycosis by inducing iron starvation (1, 41, 
42). The ESCMID guidelines conclude that there is only a marginal recommendation to 
use deferasirox outside clinical trials of hematological patients, for diabetic patients (14).  
Salvage treatment with posaconazole 200 mg orally four times daily has been described 
and is strongly recommended in cases of refractoriness of disease, intolerance of other 
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antifungals or a combination of both (14). 
 
The duration of treatment of invasive mold infections should be individualized and 
continued until the clinical signs, immunosuppression and radiological signs, if present, 
resolves (1, 14). Testing for resistance should be guided by local epidemiology but it is 
suggested to test Aspergillus fumigatus for itraconazole and voriconazole susceptibility 
(16). In general, for rare invasive fungal infections, the latest ESCMID guidelines to date 
suggest administering amphotericin B (lipid formulation) in combination with flucytosine for 
better drug penetration, depending on susceptibility of the fungal species (14).  
 
7. CONCLUSION 
 
Fungal infections in the ICU (Intensive Care Unit) are of great importance because they 
are associated with high mortality and morbidity. Despite growing knowledge about the 
epidemiology and risk factors for developing invasive fungal infections, it still remains a 
challenge to diagnose and treat these infections in the critical care setting. Combinations 
of different diagnostic tests seem to be the most prudent approach. Early intervention 
strategies are crucial and the use of personalized risk profiling based on immunogenetics 
might be a useful approach in the future, even though more studies are needed. The 
management of invasive fungal infections has changed in the last few years partly due to 
growing resistance to antifungal drugs and timely use of drugs is necessary to avoid 
further changing the ecology of the fungal species. 
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